Objectives: Neuropeptide Y (NPY) plays a central in energy homeostasis and potentially in the development of obesity-related comorbidities, like type II diabetes. As the PreproNPY Leu7Pro polymorphism probably changes the intracellular processing of the synthesized preproNPY peptide, we assessed the hypothesis that PreproNPY Leu7Pro polymorphism is a risk factor for type II diabetes, impaired glucose tolerance and hypertension. Design: Blood pressure recordings and oral glucose tolerance test were performed in the hypertensive (n ¼ 515) and control cohorts (n ¼ 525) of our well-defined Oulu Project Elucidating Risk of Atherosclerosis (OPERA) study. The prevalence of type II diabetes was 9% (n ¼ 93). The genotypes, insulin and glucose metabolism indexes and plasma ghrelin of the subjects were determined. Results: Pro7 allele frequencies were 5.9, 5.3 and 11.3% in the total cohort, in subjects without and with type II diabetes, respectively. The PreproNPY Pro7 carrier status was a significant risk factor for type II diabetes, and the effect remained significant after adjustment for age, sex, waist circumference and study group (odds ratio ¼ 3.02, confidence interval: 1.67-5.44 and Po0.001). Pro7 carriers were more insulin resistant and showed lower ghrelin levels compared to non-carriers. Conclusions: The PreproNPY Pro7 allele is associated with an increased risk for type II diabetes. The risk seems to be associated with a higher insulin resistance among Pro7 carriers whereas low ghrelin concentrations in Pro7 carriers are possibly a consequence of high insulin levels. Sponsorship: None. 
Introduction
Central mechanisms including the activation of hypothalamic neuropeptide Y (NPY) control energy homeostasis (Williams et al., 2001) . As most of the patients with type II diabetes are obese, NPY is also potentially involved in the development of obesity-related comorbidities, like type II diabetes. NPY is, therefore, a good candidate gene for type II diabetes. The functional leucine 7 to proline (Leu7Pro) polymorphism in the signal peptide of NPY has been earlier associated with plasma NPY levels (Kallio et al., 2001 (Kallio et al., , 2003 , insulin metabolism (Kallio et al., 2003; Jaakkola et al., 2005) , type II diabetes (Nordman et al., 2005) and its complications (Niskanen et al., 2000a, b; Koulu et al., 2004) . The results have been, however, contradictory, and the mechanisms behind these associations largely unknown. Interestingly, the PreproNPY Leu7Pro polymorphism has been associated with delayed ghrelin suppression during oral glucose tolerance test (Jaakkola et al., 2005) . The orexigenic potency of ghrelin is suggested to be caused by the activation of hypothalamic NPY neurones (Shintani et al., 2001) . We have earlier reported an association of low plasma ghrelin with type II diabetes (Pöykkö et al., 2003) . We assessed the hypothesis that PreproNPY Leu7Pro polymorphism is a risk factor for type II diabetes, impaired glucose tolerance (IGT), and hypertension. Secondly, we studied whether Leu7Pro polymorphism is associated with ghrelin plasma levels.
Materials and methods
Subjects OPERA (Oulu Project Elucidating Risk of Atherosclerosis) is a population-based epidemiological study addressing the risk factors and disease end points of atherosclerotic cardiovascular diseases. The study population and the selection criteria have been described in detail elsewhere (Rantala et al., 1999) . In short, 600 hypertensive subjects (300 men and 300 women aged 40-59) were randomly selected from the national register for reimbursement of the costs of antihypertensive medication. For each hypertensive subject, an age-and sex-matched control subject was randomly selected. In all, 1040 subjects participated in the study. The study was conducted according to the principles of the Declaration of Helsinki.
Biomedical factors and laboratory analyses
At the visit, anthropometric measurements (weight, height, waist and hip), blood pressure measurements and an oral glucose tolerance test with 75 g of glucose were performed. Plasma was separated from venous blood and stored for further analyses. Blood insulin and glucose levels were determined at 0, 60 and 120 min (Rantala et al., 1999) . Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using the following formula: (fasting plasma insulin Â plasma glucose)/22.5 (Matthews et al., 1985) . All the laboratory test samples were obtained after an overnight fast.
Waist circumference was measured to the nearest 0.5 cm with a tape measure midway between the lower rib margin and the iliac crest in light expirium. Blood pressure was measured according to the recommendations of the American Society of Hypertension in a sitting position from the right arm with an oscillometric device (Dinamap model 18465X, Criticon Ltd, Ascot, UK) after an overnight fast and after a 10-15-min rest. Three measurements were made at 1-min intervals and the means of the last two were used in the analyses.
Type II diabetes and IGT were determined according to the WHO criteria. A commercial RIA kit recognizing both acylated and de-acylated ghrelin was used (Phoenix Pharmaceuticals Inc., Belmont, CA, USA). The routine clinical laboratory tests were carried out in the Central Laboratory of the Oulu University Hospital.
Genotyping of the Leu7Pro polymorphism was performed as described earlier (Koulu et al., 2004) . To normalize the skewed distributions of glucose and insulin parameters, log-transformed values were used when appropriate. All calculations were made with the SPSS (version 9.0; SPSS Inc.) statistical package. All the tests performed were two sided.
Statistical methods

Results
Genotype frequencies were in a Hardy-Weinberg equilibrium. The prevalence of type II diabetes was 9% (n ¼ 93). The mean age of subjects with diabetes was 53.2 (5.4) years, mean body mass index (BMI) 31.3 (5.2) kg/m 2 and mean hemoglobin A1c 8.7 (2.6)%. As we have already reported, plasma ghrelin levels were lower among diabetics than nondiabetics (Pöykkö et al., 2003) . The mean hemoglobin A1c of the total cohort was 6.6 (1.7)% and the mean waist circumference was 90.6 (13.2) cm. The allele frequency of PreproNPY Pro7 was 5.9% in the total cohort. Pr7o allele frequencies were 5.3 and 11.3% in subjects without and with type II diabetes, respectively. The main characteristics of the study subjects by PreproNPY Leu7Pro genotypes are presented in Table 1 . In the total cohort, Pro7 carriers had lower levels of ghrelin but higher levels of fasting glucose and higher HOMA-IR index. The association of Pro7 with HOMA-IR index persisted (Po0.05) after adjustments for age, study group, sex and waist circumference were performed. When adjusted for the effect of age, BMI, sex and study group, Pro7 remained a significant predictor of ghrelin levels (Po0.03). In the hypertensive cohort Pro7 allele was associated with higher fasting glucose and higher HOMA-IR index, whereas in the control cohort it was associated with lower ghrelin levels.
In the total cohort, the Pro7 allele was a significant risk factor for type II diabetes (w 2 ¼ 10.7, df ¼ 1 and P ¼ 0.003).
The effect of the PreproNPY Pro7 allele as a risk factor for type II diabetes was also evident in the logistic regression model (covariates age, sex, study group and waist circumference) of the total cohort (odds ratio (OR) ¼ 3.02, confidence interval (CI): 1.67-5.44, Po0.001) or only the hypertensive cohort (OR ¼ 4.10, CI: 2.03-8.28, Po0.001). However, the Leu7Pro polymorphism was not associated with the prevalence of IGT (data not shown) or hypertension.
PreproNPY Leu7Pro variant and type II diabetes O Ukkola and YA Kesäniemi
Discussion
The results of the present study suggest that the PreproNPY 7Pro carrier status is associated with a threefold increased risk for type II diabetes even after adjustment for conventional risk factors. The results are in accordance with a recent report in Swedish men (Nordman et al., 2005) although in the present study the association was positive in both sexes. PreproNPY Leu7Pro polymorphism has been linked to accelerated atherosclerosis (Niskanen et al., 2000a) and progression of diabetic retinopathy (Niskanen et al., 2000b; Koulu et al., 2004) in type II diabetic subjects. Some studies have also related the Leu7Pro polymorphism with decreased insulin secretion (Jaakkola et al., 2005) and lower free fatty acid levels both in the fasting state and during the hyperinsulinemic clamp (Pihlajamäki et al., 2003) . In contrast with these findings, carriers of the Pro7 allele in the current study were more insulin resistant according to HOMA-IR values. How could the Leu7Pro polymorphism affect insulin sensivitity? As the PreproNPY Leu7Pro polymorphism probably changes the intracellular processing of the synthesized preproNPY peptide (Kallio et al., 2001) , it is a functional variant. The storage or kinetics of NPY release could be modified in subjects having this polymorphism. This could have an effect on body weight regulation as has already been reported by some investigators (Mattevi et al., 2002) . However, in the current study the PreproNPY Leu7Pro polymorphism was not associated with body weight regulation. NPY is among the factors that are able to augment sympathetic activation (Egan, 2003) and this could be changed as a consequence of functional genetic variant. Sympathetic hyperfunction may be involved in the pathogenesis of IR (Egan, 2003) .
Low ghrelin is a risk factor for type II diabetes (Pöykkö et al., 2003) . The effects of ghrelin are suggested to be caused by the activation of hypothalamic NPY neurones in the arcuate nucleus which are inhibited by insulin and leptin (Shintani et al., 2001) . The suppression of ghrelin concentrations after glucose ingestion has been shown to be delayed in Leu7Pro subjects (Jaakkola et al., 2005) . We observed ghrelin levels to be lower among Pro7 carriers. The latter notion supports the hypothesis that low ghrelin levels are somehow related to higher frequency of type II diabetes among Pro7 carriers. Low ghrelin levels among Pro7 carriers could be a consequence of increased IR or, alternatively, it could have causal effects on the development of type II diabetes. The definite role of ghrelin in glucose and insulin metabolism is unclear and other mechanisms are probably involved.
Although an association was seen between Leu7Pro and type II diabetes, there was no association with the prevalence of IGT. This lack of association was perhaps due to a lack of power.
In conclusion, our data suggests that the PreproNPY Pro7 allele may be associated with an increased risk for type II diabetes. The risk seems to be associated with a higher IR among Pro7 carriers whereas low ghrelin concentrations in Pro7 carriers are possibly a consequence of high insulin levels. Table 1 Main characteristics of the study subjects by the PrepoNPY Leu7Pro polymorphism
Control cohort
Hypertensive cohort All P ¼ probability for the difference between genotypes in ANCOVA adjusted for sex (control subjects and hypertensive subjects) or sex and study group (all subjects). HOMA-IR index was also adjusted for age and waist circumference.
